This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)

Tipranks - Tipranks - Wed Jun 17, 6:52AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Irhythm Technologies (IRTC), Gilead Sciences (GILD) and Disc Medicine (IRON) with bullish sentiments.

Claim 55% Off TipRanks

Irhythm Technologies (IRTC)

Truist Financial analyst Richard Newitter maintained a Buy rating on Irhythm Technologies today. The company’s shares closed last Monday at $113.76.

According to TipRanks.com, Newitter is a 4-star analyst with an average return of 6.8% and a 47.2% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

Irhythm Technologies has an analyst consensus of Strong Buy, with a price target consensus of $177.36, representing a 54.7% upside. In a report issued on June 1, Canaccord Genuity also maintained a Buy rating on the stock with a $152.00 price target.

See today’s best-performing stocks on TipRanks >>

Gilead Sciences (GILD)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Gilead Sciences. The company’s shares closed last Monday at $124.30.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 15.5% and a 46.9% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.37, implying a 28.0% upside from current levels. In a report issued on June 2, Bank of America Securities also maintained a Buy rating on the stock with a $162.00 price target.

Disc Medicine (IRON)

In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Disc Medicine. The company’s shares closed last Monday at $70.09.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 13.1% and a 54.0% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Rapport Therapeutics, Inc., and Praxis Precision Medicines. ;'>

Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $101.50, which is a 47.0% upside from current levels. In a report issued on June 3, TD Cowen also initiated coverage with a Buy rating on the stock.

Read More on IRTC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).